DM-506 explained

Drug Name:DM-506
Width:200px
C:13
H:16
N:2
Iupac Name:3-methyl-2,4,5,6-tetrahydro-1H-azepino[4,5-b]indole
Cas Number:7546-66-9
Chemspiderid:22605
Pubchem:24183
Smiles:CN1CCC2=C(CC1)NC3=CC=CC=C23
Stdinchi:1S/C13H16N2/c1-15-8-6-11-10-4-2-3-5-12(10)14-13(11)7-9-15/h2-5,14H,6-9H2,1H3
Stdinchikey:WBCPONKOWIDTJM-UHFFFAOYSA-N

DM-506 (ibogaminalog) is a drug first invented in the 1960s,[1] which acts as both a partial agonist at the 5-HT2A receptor, and a negative allosteric modulator at the α7 and α9α10 nicotinic acetylcholine receptors. It can be regarded as a structurally simplified derivative of ibogaine and has been researched both for anti-addictive effects and for the treatment of neuropathic pain.[2] [3] [4] [5] [6]

See also

Notes and References

  1. US . 3529062 . Indole derivatives as antitussive agents. . Renner U . Novartis Corp. . 15 September 1970 .
  2. Tae HS, Ortells MO, Yousuf A, Xu SQ, Akk G, Adams DJ, Arias HR . Tabernanthalog and ibogainalog inhibit the α7 and α9α10 nicotinic acetylcholine receptors via different mechanisms and with higher potency than the GABAA receptor and CaV2.2 channel . Biochemical Pharmacology . 223 . 116183 . May 2024 . 38580167 . 10.1016/j.bcp.2024.116183 . 11151864 . May 1, 2025 .
  3. Arias HR, Micheli L, Rudin D, Bento O, Borsdorf S, Ciampi C, Marin P, Ponimaskin E, Manetti D, Romanelli MN, Ghelardini C, Liechti ME, Di Cesare Mannelli L . 6 . Non-hallucinogenic compounds derived from iboga alkaloids alleviate neuropathic and visceral pain in mice through a mechanism involving 5-HT2A receptor activation . Biomedicine & Pharmacotherapy . 177 . 116867 . June 2024 . 38889634 . 10.1016/j.biopha.2024.116867 . 2158/1371514 . free .
  4. Arias HR, Rudin D, Hines DJ, Contreras A, Gulsevin A, Manetti D, Anouar Y, De Deurwaerdere P, Meiler J, Romanelli MN, Liechti ME, Chagraoui A . 6 . The novel non-hallucinogenic compound DM506 (3-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole) induces sedative- and anxiolytic-like activity in mice by a mechanism involving 5-HT2A receptor activation . European Journal of Pharmacology . 966 . 176329 . March 2024 . 38253116 . 10.1016/j.ejphar.2024.176329 . 2158/1354752 . free .
  5. Looschen K, Khatri SN, Maulik M, Salisbury C, Carman AF, Corriveau K, Smith C, Manetti D, Romanelli MN, Arias HR, Gipson CD, Mitra S . 6 . Novel psychoplastogen DM506 reduces cue-induced heroin-seeking and inhibits tonic GABA currents in the Prelimbic Cortex . Neurochemistry International . 178 . 105785 . June 2024 . 38838988 . 10.1016/j.neuint.2024.105785 . 2158/1371513 . free .
  6. Tae HS, Ortells MO, Tekarli BJ, Manetti D, Romanelli MN, McIntosh JM, Adams DJ, Arias HR . 6 . DM506 (3-Methyl-1,2,3,4,5,6-hexahydroazepino[4,5-<i>b</i>]indole fumarate), a Novel Derivative of Ibogamine, Inhibits α7 and α9α10 Nicotinic Acetylcholine Receptors by Different Allosteric Mechanisms . ACS Chemical Neuroscience . 14 . 14 . 2537–2547 . July 2023 . 37386821 . 10.1021/acschemneuro.3c00212 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "DM-506".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.